Stock NEURODERM LTD
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Neuroderm Ltd

Equities

IL0011334955

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation
GL
Neuroderm : Stocks Under Scanner in the Biotech Space -- Merrimack Pharma, MannKind, NeuroDerm, and Celsion
PR
NeuroDerm Announces Second Quarter 2017 Financial Results
GL
NeuroDerm Announces Extraordinary General Meeting of Shareholders to Approve Acquisition by Mitsubishi Tanabe Pharma Corporation
GL
NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash
GL
Results of NeuroDerm’s ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of Neurology
GL
NeuroDerm Presents Six Posters at the 21st International Congress of Parkinson’s Disease and Movement Disorders
GL
European Medicines Agency Accepts Design of NeuroDerm’s ND0612 Phase III iNDiGO Efficacy Trial
GL
NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders
GL
NeuroDerm CEO to Present at the Jefferies Global Healthcare Conference on June 7, 2017
GL
NeuroDerm ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders
GL
NeuroDerm Announces First Quarter 2017 Financial Results
GL
NeuroDerm to Ring the Nasdaq Stock Market Opening Bell and Participate in the Parkinson’s Unity Walk
GL
NeuroDerm to Host Investor Day on April 21, 2017
GL
NeuroDerm Announces Fourth Quarter and Full Year 2016 Financial Results
GL
NeuroDerm to Host Fourth Quarter and 2016 Fiscal Year Financial Results Conference Call on March 30, 2017
GL
NeuroDerm Achieves Primary Endpoint in ND0612H Phase II Trial for Advanced Parkinson’s Disease; Seeks Broader EU Label Based on iNDiGO Trial Following EMA Meeting
GL
NeuroDerm CEO to Present at Upcoming Investor Conferences
GL
NeuroDerm Announces Extraordinary General Meeting of Shareholders
GL
NeuroDerm CEO to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 12, 2017
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Neuroderm Ltd